Lv1
100 积分 2024-11-03 加入
Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
1个月前
已完结
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
1个月前
已关闭
The role of menin inhibitors in acute myeloid leukemia
1个月前
已关闭
Epigenetic Regulation of Non-canonical Menin Targets Modulates Menin Inhibitor Response in Acute Myeloid Leukemia
1个月前
已完结
Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors
2个月前
已完结
Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
2个月前
已关闭
Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
2个月前
已关闭
Menin Inhibitors in KMT2A-Rearranged and NPM1-Mutated Acute Leukemia: A Scoping Review of Safety and Efficacy
2个月前
已关闭
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
2个月前
已完结
Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant
2个月前
已关闭
皖公网安备34019202002308
